glp 1 agonist schizophrenia GLP-1 mimetics and cognition GLP-1 agonist semaglutide reduced diabetes

Corriere MD, Minang LB, Sisson SD, et al

Based on evidence for the contribution of hyperglucagonemia to hyperglycaemia in T2D, research demonstrated the use of glucagon antagonism to improve glycaemic control

Exp Opin Pharmacother 21:21012114

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Hussein, G

The company hopes to capture a large share of Indias semaglutide market, which Lupin chief financial officer Ramesh Swaminathan said in an interview with CNBC could be worth $1 billion per year